Matrix metalloproteinase (MMP)-2 gene polymorphisms affect circulating MMP-2 levels in patients with migraine with aura

Gene

Volumn 512, Issue 1, 2013, Pages 35-40

  Gonçalves, Flavia M ^a   Martins Oliveira, Alisson ^b   Lacchini, Riccardo ^b   Belo, Vanessa A ^b   Speciali, Jose G ^b   Dach, Fabíola ^b   Tanus Santos, Jose E ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Haplotype; Matrix metalloproteinase 2; Migraine; Polymorphisms; TIMP 2

Indexed keywords

GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ALLELE; ARTICLE; BLOOD BRAIN BARRIER; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DNA ISOLATION; DNA POLYMORPHISM; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEADACHE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

ADULT; EPILEPSY; FEMALE; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MIGRAINE WITH AURA; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84868617420     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.09.109     Document Type: Article

References (43)

1. Anon The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004, 24(Suppl. 1):9-160.
2. Ashina M., Tvedskov J.F., Lipka K., Bilello J., Penkowa M., Olesen J. Matrix metalloproteinases during and outside of migraine attacks without aura. Cephalalgia 2010, 30:303-310.
3. Bernecker C., et al. Increased matrix metalloproteinase activity is associated with migraine and migraine-related metabolic dysfunctions. Eur. J. Neurol. 2011, 18:571-576.
4. Bigal M.E., et al. Migraine and cardiovascular disease: a population-based study. Neurology 2010, 74:628-635.
5. Castro M.M., Tanus-Santos J.E., Gerlach R.F. Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol. Res. 2011, 64:567-572.
6. Ceron C.S., et al. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br. J. Pharmacol. 2010, 160:77-87.
7. Ceron C.S., et al. Time course involvement of matrix metalloproteinases in the vascular alterations of renovascular hypertension. Matrix Biol. 2012, 31:261-270.
8. Crawford D.C., Nickerson D.A. Definition and clinical importance of haplotypes. Annu. Rev. Med. 2005, 56:303-320.
9. Dhillon O.S., et al. Matrix metalloproteinase-2 predicts mortality in patients with acute coronary syndrome. Clin. Sci. (Lond.) 2010, 118:249-257.
10. Edvinsson L., Tfelt-Hansen P. The blood-brain barrier in migraine treatment. Cephalalgia 2008, 28:1245-1258.
11. Ehrlich J.R., Kaluzny M., Baumann S., Lehmann R., Hohnloser S.H. Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation. Clin. Res. Cardiol. 2011, 100:1029-1036.
12. Feng S., et al. Matrix metalloproteinase-2 and -9 secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight junction proteins. PLoS One 2011, 6:e20599.
13. Fontana V., Silva P.S., Gerlach R.F., Tanus-Santos J.E. Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin. Chim. Acta 2012, 413:656-662.
14. Galletti F., Cupini L.M., Corbelli I., Calabresi P., Sarchielli P. Pathophysiological basis of migraine prophylaxis. Prog. Neurobiol. 2009, 89:176-192.
15. Gerlach R.F., Demacq C., Jung K., Tanus-Santos J.E. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin. Biochem. 2007, 40:119-123.
16. Gursoy-Ozdemir Y., et al. Cortical spreading depression activates and upregulates MMP-9. J. Clin. Invest. 2004, 113:1447-1455.
17. Heo J.H., Lucero J., Abumiya T., Koziol J.A., Copeland B.R., del Zoppo G.J. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J. Cereb. Blood Flow Metab. 1999, 19:624-633.
18. Jacob-Ferreira A.L., Lacchini R., Gerlach R.F., Passos C.J., Barbosa F., Tanus-Santos J.E. A common matrix metalloproteinase (MMP)-2 polymorphism affects plasma MMP-2 levels in subjects environmentally exposed to mercury. Sci. Total. Environ. 2011, 409:4242-4246.
19. Jensen R., Stovner L.J. Epidemiology and comorbidity of headache. Lancet Neurol. 2008, 7:354-361.
20. Kurth T., Chabriat H., Bousser M.G. Migraine and stroke: a complex association with clinical implications. Lancet Neurol. 2012, 11:92-100.
21. Lacchini R., Metzger I.F., Luizon M., Ishizawa M., Tanus-Santos J.E. Interethnic differences in the distribution of matrix metalloproteinases genetic polymorphisms are consistent with interethnic differences in disease prevalence. DNA Cell Biol. 2010, 29:649-655.
22. Lacchini R., et al. Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J. Hum. Hypertens. 2012, 26:171-177.
23. Liu J., Jin X., Liu K.J., Liu W. Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage. J. Neurosci. 2012, 32:3044-3057.
24. Marson B.P., et al. Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney disease. Am. J. Nephrol. 2012, 35:209-215.
25. Martins-Oliveira A., et al. Different circulating metalloproteinases profiles in women with migraine with and without aura. Clin. Chim. Acta 2009, 408:60-64.
26. Palei A.C., et al. Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy. Exp. Mol. Pathol. 2012, 92:217-221.
27. Pietrobon D., Striessnig J. Neurobiology of migraine. Nat. Rev. Neurosci. 2003, 4:386-398.
28. Price S.J., Greaves D.R., Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J. Biol. Chem. 2001, 276:7549-7558.
29. Raffetto J.D., Khalil R.A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 2008, 75:346-359.
30. Rist P.M., Buring J.E., Kase C.S., Schurks M., Kurth T. Migraine and functional outcome from ischemic cerebral events in women. Circulation 2010, 122:2551-2557.
31. Romi F., Helgeland G., Gilhus N.E. Serum levels of matrix metalloproteinases: implications in clinical neurology. Eur. Neurol. 2012, 67:121-128.
32. Rosenberg G.A. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009, 8:205-216.
33. Rosenberg G.A., Kornfeld M., Estrada E., Kelley R.O., Liotta L.A., Stetler-Stevenson W.G. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res. 1992, 576:203-207.
34. Rosenberg G.A., Estrada E.Y., Dencoff J.E. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998, 29:2189-2195.
35. Saracini C., et al. Polymorphisms of genes involved in extracellular matrix remodeling and abdominal aortic aneurysm. J. Vasc. Surg. 2012, 55:171 e2-179 e2.
36. Sbardella D., et al. Human matrix metalloproteinases: an ubiquitarian class of enzymes involved in several pathological processes. Mol. Aspects Med. 2012, 33:119-208.
37. Sousa-Santos O., et al. Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during acute pulmonary thromboembolism. Naunyn Schmiedebergs Arch. Pharmacol. 2012, 385:685-696.
38. Stephens M., Smith N.J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 2001, 68:978-989.
39. Wang Z., Xue Y., Jiao H., Liu Y., Wang P. Doxycycline-mediated protective effect against focal cerebral ischemia-reperfusion injury through the modulation of tight junctions and PKCdelta signaling in rats. J. Mol. Neurosci. 2012, 47:89-100.
40. Yang Y., Rosenberg G.A. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke 2011, 42:3323-3328.
41. Yang Y., Estrada E.Y., Thompson J.F., Liu W., Rosenberg G.A. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J. Cereb. Blood Flow Metab. 2007, 27:697-709.
42. Yu C., Zhou Y., Miao X., Xiong P., Tan W., Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res. 2004, 64:7622-7628.
43. Zhou Y., et al. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis 2005, 26:1117-1121.